English

AEGLEA BIOTHERAPEUTICS, INC.

EDGAR

AGLE Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-37.2 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -157410000 USD Source
Operating Cash Flow: -120211000 USD Source

Cash and cash equivalents: 162 million USD 2026-06-30 Source
Exact value

162007000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 88.1 million shares 2026-06-30 Source
Exact value

88064133 shares

Reported share-count change

45.87% · 27.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

60372927 shares · 2025-06-30· Source
88064133 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 0 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 0 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 0 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 0 USD · 2024-01-01 – 2024-09-30 Source

Net income

-179 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -11183000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -155203000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -92673000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -69005000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -36200000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-209 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -124674000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -87557000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -169252000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -124674000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -57372000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -127249000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -57372000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2024-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AEGLEA BIOTHERAPEUTICS, INC. · 2025-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1259339 Filing: 000163628226000020 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1259986 Filing: 000163628226000020
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 52.82 million

Prior period

−USD 208.02 million

2024-01-01 – 2024-12-31
Current period

−USD 155.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-155203000 − -208018000 = 52815000 USD

-208018000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-155203000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AEGLEA BIOTHERAPEUTICS, INC. · 2025-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Year-over-year change in Net income: 52815000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -155203000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1588006 Filing: 000163628226000020 Input fundies:NetIncome: -208018000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1588768 Filing: 000163628226000020
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 11.84 million

Prior period

−USD 157.41 million

2024-01-01 – 2024-12-31
Current period

−USD 169.25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-169252000 − -157410000 = -11842000 USD

-157410000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-169252000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2025-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Year-over-year change in Operating cash flow: -11842000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -169252000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1628952 Filing: 000163628226000020 Input fundies:OperatingCashFlow: -157410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1629599 Filing: 000163628226000020
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 209.56 million
Operating income −USD 209.56 million
Tax, interest and other Derived −USD 54.36 million
Net income −USD 155.2 million

Cash

Operating cash flow −USD 169.25 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 573% of revenue.
2017 Operating loss: operating costs were 632% of revenue.
2018 Operating loss: operating costs were 1,266% of revenue.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 450% of revenue.
2022 Operating loss: operating costs were 3,740% of revenue.
2023 Operating loss: operating costs were 27,448% of revenue.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	4628000	26534000 Derived	-21906000	-208000 Derived	-21698000	-19052000 Derived	Source 2016-01-01 – 2016-12-31: 4628000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -21906000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -21698000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -18840000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 212000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	5205000	32881000 Derived	-27676000	-440000 Derived	-27236000	-25234000 Derived	Source 2017-01-01 – 2017-12-31: 5205000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -27676000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -27236000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -24615000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 619000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	3900000	49363000 Derived	-45463000	-1115000 Derived	-44348000	-32615000 Derived	Source 2018-01-01 – 2018-12-31: 3900000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -45463000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -44348000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -32193000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 422000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	0	80334000 Derived	-80334000	-2080000 Derived	-78254000	-67184000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -80334000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -78254000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -65692000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1492000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	81481000 Derived	-81481000	-588000 Derived	-80893000	-80055000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -81481000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -80893000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -75775000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 4280000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	18739000	84388000 Derived	-65649000	152000 Derived	-65801000	-54289000 Derived	Source 2021-01-01 – 2021-12-31: 18739000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -65649000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -65801000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -53716000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 573000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2329000	87110000 Derived	-84781000	-966000 Derived	-83815000	-80182000 Derived	Source 2022-01-01 – 2022-12-31: 2329000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -84781000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -83815000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -80144000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 38000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	886000	243189000 Derived	-242303000	96487000 Derived	-338790000	-99910000 Derived	Source 2023-01-01 – 2023-12-31: 886000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -242303000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -338790000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -99910000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	208566000 Derived	-208566000	-548000 Derived	-208018000	-157410000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -208566000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -208018000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -157410000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	209562000 Derived	-209562000	-54359000 Derived	-155203000	Unavailable	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -209562000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -155203000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -169252000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	4628000	Revenue: 4628000 Open source
20172017-12-31	Revenue	5205000	Revenue: 5205000 Open source
20182018-12-31	Revenue	3900000	Revenue: 3900000 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	18739000	Revenue: 18739000 Open source
20222022-12-31	Revenue	2329000	Revenue: 2329000 Open source
20232023-12-31	Revenue	886000	Revenue: 886000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 4628000 Open source
20172017-12-31	Year over year	12.5%	Revenue: 5205000 Open source Revenue: 4628000 Open source
20182018-12-31	Year over year	-25.1%	Revenue: 3900000 Open source Revenue: 5205000 Open source
20192019-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 3900000 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 18739000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	-87.6%	Revenue: 2329000 Open source Revenue: 18739000 Open source
20232023-12-31	Year over year	-62%	Revenue: 886000 Open source Revenue: 2329000 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 886000 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -27,348% 2023

Net margin -38,238.1% 2023

Free cash flow margin -11,276.5% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-473.3%	Operating Income: -21906000 Open source Revenue: 4628000 Open source
20172017-12-31	Operating margin	-531.7%	Operating Income: -27676000 Open source Revenue: 5205000 Open source
20182018-12-31	Operating margin	-1,165.7%	Operating Income: -45463000 Open source Revenue: 3900000 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -80334000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -81481000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-350.3%	Operating Income: -65649000 Open source Revenue: 18739000 Open source
20222022-12-31	Operating margin	-3,640.2%	Operating Income: -84781000 Open source Revenue: 2329000 Open source
20232023-12-31	Operating margin	-27,348%	Operating Income: -242303000 Open source Revenue: 886000 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -208566000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -209562000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	-468.8%	Net Income: -21698000 Open source Revenue: 4628000 Open source
20172017-12-31	Net margin	-523.3%	Net Income: -27236000 Open source Revenue: 5205000 Open source
20182018-12-31	Net margin	-1,137.1%	Net Income: -44348000 Open source Revenue: 3900000 Open source
20192019-12-31	Net margin	Not reported	Net Income: -78254000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -80893000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-351.1%	Net Income: -65801000 Open source Revenue: 18739000 Open source
20222022-12-31	Net margin	-3,598.8%	Net Income: -83815000 Open source Revenue: 2329000 Open source
20232023-12-31	Net margin	-38,238.1%	Net Income: -338790000 Open source Revenue: 886000 Open source
20242024-12-31	Net margin	Not reported	Net Income: -208018000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -155203000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	-411.7%	Revenue: 4628000 Open source Operating Cash Flow: -18840000 Open source Capital Expenditure: 212000 Open source
20172017-12-31	Free cash flow margin	-484.8%	Revenue: 5205000 Open source Operating Cash Flow: -24615000 Open source Capital Expenditure: 619000 Open source
20182018-12-31	Free cash flow margin	-836.3%	Revenue: 3900000 Open source Operating Cash Flow: -32193000 Open source Capital Expenditure: 422000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -65692000 Open source Capital Expenditure: 1492000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -75775000 Open source Capital Expenditure: 4280000 Open source
20212021-12-31	Free cash flow margin	-289.7%	Revenue: 18739000 Open source Operating Cash Flow: -53716000 Open source Capital Expenditure: 573000 Open source
20222022-12-31	Free cash flow margin	-3,442.8%	Revenue: 2329000 Open source Operating Cash Flow: -80144000 Open source Capital Expenditure: 38000 Open source
20232023-12-31	Free cash flow margin	-11,276.5%	Revenue: 886000 Open source Operating Cash Flow: -99910000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -157410000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -169252000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -169.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-18840000	Operating Cash Flow: -18840000 Open source
20172017-12-31	Operating cash flow	-24615000	Operating Cash Flow: -24615000 Open source
20182018-12-31	Operating cash flow	-32193000	Operating Cash Flow: -32193000 Open source
20192019-12-31	Operating cash flow	-65692000	Operating Cash Flow: -65692000 Open source
20202020-12-31	Operating cash flow	-75775000	Operating Cash Flow: -75775000 Open source
20212021-12-31	Operating cash flow	-53716000	Operating Cash Flow: -53716000 Open source
20222022-12-31	Operating cash flow	-80144000	Operating Cash Flow: -80144000 Open source
20232023-12-31	Operating cash flow	-99910000	Operating Cash Flow: -99910000 Open source
20242024-12-31	Operating cash flow	-157410000	Operating Cash Flow: -157410000 Open source
20252025-12-31	Operating cash flow	-169252000	Operating Cash Flow: -169252000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -157.4M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-19052000	Operating Cash Flow: -18840000 Open source Capital Expenditure: 212000 Open source
20172017-12-31	Free cash flow	-25234000	Operating Cash Flow: -24615000 Open source Capital Expenditure: 619000 Open source
20182018-12-31	Free cash flow	-32615000	Operating Cash Flow: -32193000 Open source Capital Expenditure: 422000 Open source
20192019-12-31	Free cash flow	-67184000	Operating Cash Flow: -65692000 Open source Capital Expenditure: 1492000 Open source
20202020-12-31	Free cash flow	-80055000	Operating Cash Flow: -75775000 Open source Capital Expenditure: 4280000 Open source
20212021-12-31	Free cash flow	-54289000	Operating Cash Flow: -53716000 Open source Capital Expenditure: 573000 Open source
20222022-12-31	Free cash flow	-80182000	Operating Cash Flow: -80144000 Open source Capital Expenditure: 38000 Open source
20232023-12-31	Free cash flow	-99910000	Operating Cash Flow: -99910000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow	-157410000	Operating Cash Flow: -157410000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -169252000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	6.1%	Total Liabilities: 4097000 Open source Total Assets: 67063000 Open source
20172017-12-31	Liabilities / assets	10.2%	Total Liabilities: 5740000 Open source Total Assets: 56077000 Open source
20182018-12-31	Liabilities / assets	13.3%	Total Liabilities: 10311000 Open source Total Assets: 77739000 Open source
20192019-12-31	Liabilities / assets	27.8%	Total Liabilities: 23102000 Open source Total Assets: 83183000 Open source
20202020-12-31	Liabilities / assets	13.5%	Total Liabilities: 21786000 Open source Total Assets: 161618000 Open source
20212021-12-31	Liabilities / assets	23.6%	Total Liabilities: 25985000 Open source Total Assets: 109926000 Open source
20222022-12-31	Liabilities / assets	29.3%	Total Liabilities: 20839000 Open source Total Assets: 71144000 Open source
20232023-12-31	Liabilities / assets	21.4%	Total Liabilities: 73288000 Open source Total Assets: 341859000 Open source
20242024-12-31	Liabilities / assets	14.9%	Total Liabilities: 90680000 Open source Total Assets: 608484000 Open source
20252025-12-31	Liabilities / assets	8%	Total Liabilities: 62545000 Open source Total Assets: 777781000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.25× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	16.75×	Current Assets: 66424000 Open source Current Liabilities: 3965000 Open source
20172017-12-31	Current assets / current liabilities	9.77×	Current Assets: 54991000 Open source Current Liabilities: 5629000 Open source
20182018-12-31	Current assets / current liabilities	7.49×	Current Assets: 76671000 Open source Current Liabilities: 10239000 Open source
20192019-12-31	Current assets / current liabilities	4.06×	Current Assets: 74505000 Open source Current Liabilities: 18359000 Open source
20202020-12-31	Current assets / current liabilities	9.11×	Current Assets: 149789000 Open source Current Liabilities: 16443000 Open source
20212021-12-31	Current assets / current liabilities	4.91×	Current Assets: 98891000 Open source Current Liabilities: 20144000 Open source
20222022-12-31	Current assets / current liabilities	4.25×	Current Assets: 62258000 Open source Current Liabilities: 14656000 Open source
20232023-12-31	Current assets / current liabilities	10.68×	Current Assets: 341528000 Open source Current Liabilities: 31978000 Open source
20242024-12-31	Current assets / current liabilities	11.26×	Current Assets: 608474000 Open source Current Liabilities: 54060000 Open source
20252025-12-31	Current assets / current liabilities	13.25×	Current Assets: 777781000 Open source Current Liabilities: 58685000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 21.7 million Exact value Exact value: -21698000 USD 2016-01-01 – 2016-12-31: -21698000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2016-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -21698000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21698000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/agle-20181231.xml#157219 Filing: 000156459019006771 The citation records this snapshot. The page link may show a newer release later.	−USD 18.84 million Exact value Exact value: -18840000 USD 2016-01-01 – 2016-12-31: -18840000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2016-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -18840000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18840000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/agle-20181231.xml#185800 Filing: 000156459019006771 The citation records this snapshot. The page link may show a newer release later.	USD 212,000 Exact value Exact value: 212000 USD 2016-01-01 – 2016-12-31: 212000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2016-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 212000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 212000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/agle-20181231.xml#186430 Filing: 000156459019006771 The citation records this snapshot. The page link may show a newer release later.	−USD 19.05 million Calculation and evidence -18840000 − 212000 USD Exact free cash flow: -19052000 USD 2016-01-01 – 2016-12-31: -18840000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 212000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2016-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -19052000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18840000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/agle-20181231.xml#185800 Filing: 000156459019006771 Input fundies:CapitalExpenditure: 212000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/agle-20181231.xml#186430 Filing: 000156459019006771 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 27.24 million Exact value Exact value: -27236000 USD 2017-01-01 – 2017-12-31: -27236000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2017-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -27236000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27236000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/agle-20191231.xml#145607 Filing: 000156459020005888 The citation records this snapshot. The page link may show a newer release later.	−USD 24.62 million Exact value Exact value: -24615000 USD 2017-01-01 – 2017-12-31: -24615000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2017-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -24615000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24615000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/agle-20191231.xml#171974 Filing: 000156459020005888 The citation records this snapshot. The page link may show a newer release later.	USD 619,000 Exact value Exact value: 619000 USD 2017-01-01 – 2017-12-31: 619000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2017-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 619000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 619000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/agle-20191231.xml#172605 Filing: 000156459020005888 The citation records this snapshot. The page link may show a newer release later.	−USD 25.23 million Calculation and evidence -24615000 − 619000 USD Exact free cash flow: -25234000 USD 2017-01-01 – 2017-12-31: -24615000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 619000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2017-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -25234000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24615000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/agle-20191231.xml#171974 Filing: 000156459020005888 Input fundies:CapitalExpenditure: 619000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/agle-20191231.xml#172605 Filing: 000156459020005888 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 44.35 million Exact value Exact value: -44348000 USD 2018-01-01 – 2018-12-31: -44348000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2018-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -44348000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44348000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459021014021/agle-10k_20201231.htm#1665878 Filing: 000156459021014021 The citation records this snapshot. The page link may show a newer release later.	−USD 32.19 million Exact value Exact value: -32193000 USD 2018-01-01 – 2018-12-31: -32193000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2018-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -32193000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32193000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459021014021/agle-10k_20201231.htm#1944440 Filing: 000156459021014021 The citation records this snapshot. The page link may show a newer release later.	USD 422,000 Exact value Exact value: 422000 USD 2018-01-01 – 2018-12-31: 422000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2018-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 422000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 422000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459021014021/agle-10k_20201231.htm#1960273 Filing: 000156459021014021 The citation records this snapshot. The page link may show a newer release later.	−USD 32.62 million Calculation and evidence -32193000 − 422000 USD Exact free cash flow: -32615000 USD 2018-01-01 – 2018-12-31: -32193000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 422000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2018-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -32615000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32193000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459021014021/agle-10k_20201231.htm#1944440 Filing: 000156459021014021 Input fundies:CapitalExpenditure: 422000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459021014021/agle-10k_20201231.htm#1960273 Filing: 000156459021014021 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 78.25 million Exact value Exact value: -78254000 USD 2019-01-01 – 2019-12-31: -78254000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2019-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -78254000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78254000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm#1741497 Filing: 000156459022008995 The citation records this snapshot. The page link may show a newer release later.	−USD 65.69 million Exact value Exact value: -65692000 USD 2019-01-01 – 2019-12-31: -65692000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2019-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -65692000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65692000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm#2025094 Filing: 000156459022008995 The citation records this snapshot. The page link may show a newer release later.	USD 1.49 million Exact value Exact value: 1492000 USD 2019-01-01 – 2019-12-31: 1492000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2019-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 1492000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1492000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm#2040898 Filing: 000156459022008995 The citation records this snapshot. The page link may show a newer release later.	−USD 67.18 million Calculation and evidence -65692000 − 1492000 USD Exact free cash flow: -67184000 USD 2019-01-01 – 2019-12-31: -65692000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1492000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2019-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -67184000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65692000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm#2025094 Filing: 000156459022008995 Input fundies:CapitalExpenditure: 1492000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm#2040898 Filing: 000156459022008995 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 80.89 million Exact value Exact value: -80893000 USD 2020-01-01 – 2020-12-31: -80893000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2020-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -80893000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80893000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#1701384 Filing: 000119312523302158 The citation records this snapshot. The page link may show a newer release later.	−USD 75.78 million Exact value Exact value: -75775000 USD 2020-01-01 – 2020-12-31: -75775000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2020-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -75775000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75775000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#1792955 Filing: 000119312523302158 The citation records this snapshot. The page link may show a newer release later.	USD 4.28 million Exact value Exact value: 4280000 USD 2020-01-01 – 2020-12-31: 4280000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2020-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 4280000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4280000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#1796812 Filing: 000119312523302158 The citation records this snapshot. The page link may show a newer release later.	−USD 80.06 million Calculation and evidence -75775000 − 4280000 USD Exact free cash flow: -80055000 USD 2020-01-01 – 2020-12-31: -75775000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 4280000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2020-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -80055000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -75775000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#1792955 Filing: 000119312523302158 Input fundies:CapitalExpenditure: 4280000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#1796812 Filing: 000119312523302158 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 65.8 million Exact value Exact value: -65801000 USD 2021-01-01 – 2021-12-31: -65801000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2021-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -65801000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65801000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000107/syre-20231231.htm#542506 Filing: 000163628224000107 The citation records this snapshot. The page link may show a newer release later.	−USD 53.72 million Exact value Exact value: -53716000 USD 2021-01-01 – 2021-12-31: -53716000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2021-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -53716000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53716000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000107/syre-20231231.htm#580987 Filing: 000163628224000107 The citation records this snapshot. The page link may show a newer release later.	USD 573,000 Exact value Exact value: 573000 USD 2021-01-01 – 2021-12-31: 573000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2021-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 573000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000107/syre-20231231.htm#587904 Filing: 000163628224000107 The citation records this snapshot. The page link may show a newer release later.	−USD 54.29 million Calculation and evidence -53716000 − 573000 USD Exact free cash flow: -54289000 USD 2021-01-01 – 2021-12-31: -53716000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 573000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2021-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -54289000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53716000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000107/syre-20231231.htm#580987 Filing: 000163628224000107 Input fundies:CapitalExpenditure: 573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000107/syre-20231231.htm#587904 Filing: 000163628224000107 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 83.82 million Exact value Exact value: -83815000 USD 2022-01-01 – 2022-12-31: -83815000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2022-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -83815000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83815000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1383542 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.	−USD 80.14 million Exact value Exact value: -80144000 USD 2022-01-01 – 2022-12-31: -80144000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2022-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -80144000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80144000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1424167 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.	USD 38,000 Exact value Exact value: 38000 USD 2022-01-01 – 2022-12-31: 38000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2022-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 38000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1431117 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.	−USD 80.18 million Calculation and evidence -80144000 − 38000 USD Exact free cash flow: -80182000 USD 2022-01-01 – 2022-12-31: -80144000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 38000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2022-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -80182000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80144000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1424167 Filing: 000163628225000020 Input fundies:CapitalExpenditure: 38000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1431117 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 338.79 million Exact value Exact value: -338790000 USD 2023-01-01 – 2023-12-31: -338790000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2023-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -338790000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -338790000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1589531 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	−USD 99.91 million Exact value Exact value: -99910000 USD 2023-01-01 – 2023-12-31: -99910000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2023-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -99910000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -99910000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1630247 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2023-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1430530 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.	−USD 99.91 million Calculation and evidence -99910000 − 0 USD Exact free cash flow: -99910000 USD 2023-01-01 – 2023-12-31: -99910000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2023-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -99910000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -99910000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1630247 Filing: 000163628226000020 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1430530 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 208.02 million Exact value Exact value: -208018000 USD 2024-01-01 – 2024-12-31: -208018000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2024-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -208018000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -208018000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1588768 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	−USD 157.41 million Exact value Exact value: -157410000 USD 2024-01-01 – 2024-12-31: -157410000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2024-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -157410000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -157410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1629599 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AEGLEA BIOTHERAPEUTICS, INC. · 2024-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1429945 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.	−USD 157.41 million Calculation and evidence -157410000 − 0 USD Exact free cash flow: -157410000 USD 2024-01-01 – 2024-12-31: -157410000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AEGLEA BIOTHERAPEUTICS, INC. · 2024-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Free cash flow: -157410000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -157410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1629599 Filing: 000163628226000020 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm#1429945 Filing: 000163628225000020 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 155.2 million Exact value Exact value: -155203000 USD 2025-01-01 – 2025-12-31: -155203000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AEGLEA BIOTHERAPEUTICS, INC. · 2025-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Net Income: -155203000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -155203000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1588006 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	−USD 169.25 million Exact value Exact value: -169252000 USD 2025-01-01 – 2025-12-31: -169252000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AEGLEA BIOTHERAPEUTICS, INC. · 2025-12-31 AEGLEA BIOTHERAPEUTICS, INC. (edgar:1636282) Operating Cash Flow: -169252000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:11:36Z Snapshot: 24c986242139113e85948a6ac2c95253aa5d94ce4b2df1a06dd900dabac42867 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1636282/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -169252000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm#1628952 Filing: 000163628226000020 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

165 filings · 2,436 latest values · 2,436 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001636282, 1636282, AGLE, SYRE, edgar:1636282

Also known as AEGLEA BIOTHERAPEUTICS, INC., Aeglea BioTherapeutics, Inc., SPYRE THERAPEUTICS, INC., Spyre Therapeutics, Inc.

AEGLEA BIOTHERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation